Alpha Teknova Inc (TKNO) - Net Assets
Based on the latest financial reports, Alpha Teknova Inc (TKNO) has net assets worth $64.92 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($98.66 Million) and total liabilities ($33.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Alpha Teknova Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $64.92 Million |
| % of Total Assets | 65.81% |
| Annual Growth Rate | 32.15% |
| 5-Year Change | -51.97% |
| 10-Year Change | N/A |
| Growth Volatility | 126.75 |
Alpha Teknova Inc - Net Assets Trend (2019–2025)
This chart illustrates how Alpha Teknova Inc's net assets have evolved over time, based on quarterly financial data. See TKNO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Alpha Teknova Inc (2019–2025)
The table below shows the annual net assets of Alpha Teknova Inc from 2019 to 2025. For live valuation and market cap data, see market value of Alpha Teknova Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $68.78 Million | -16.53% |
| 2024-12-31 | $82.39 Million | -8.49% |
| 2023-12-31 | $90.04 Million | -9.86% |
| 2022-12-31 | $99.89 Million | -30.25% |
| 2021-12-31 | $143.20 Million | +173.26% |
| 2020-12-31 | $52.41 Million | +305.93% |
| 2019-12-31 | $12.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alpha Teknova Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13448500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $204.56 Million | 297.44% |
| Total Equity | $68.78 Million | 100.00% |
Alpha Teknova Inc Competitors by Market Cap
The table below lists competitors of Alpha Teknova Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Lovesac Company
NASDAQ:LOVE
|
$205.38 Million |
|
Metropolitan Land Tbk
JK:MTLA
|
$205.44 Million |
|
Walchandnagar Industries Limited
NSE:WALCHANNAG
|
$205.47 Million |
|
Grupo Minsa S.A.B. de C.V
MX:MINSAB
|
$205.55 Million |
|
EMS Limited
NSE:EMSLIMITED
|
$205.30 Million |
|
CCS Supply Chain Management Co Ltd
SHG:600180
|
$205.12 Million |
|
Lotte Data Communication Company
KO:286940
|
$205.06 Million |
|
Xplora Technologies As
OL:XPLRA
|
$205.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alpha Teknova Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 82,394,000 to 68,775,000, a change of -13,619,000 (-16.5%).
- Net loss of 17,259,000 reduced equity.
- Share repurchases of 55,000 reduced equity.
- Other factors increased equity by 3,695,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.26 Million | -25.09% |
| Share Repurchases | $55.00K | -0.08% |
| Other Changes | $3.69 Million | +5.37% |
| Total Change | $- | -16.53% |
Book Value vs Market Value Analysis
This analysis compares Alpha Teknova Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.85x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.39x to 3.85x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $3.55 | $4.95 | x |
| 2020-12-31 | $13.18 | $4.95 | x |
| 2021-12-31 | $5.11 | $4.95 | x |
| 2022-12-31 | $3.56 | $4.95 | x |
| 2023-12-31 | $2.83 | $4.95 | x |
| 2024-12-31 | $1.76 | $4.95 | x |
| 2025-12-31 | $1.29 | $4.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alpha Teknova Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.59%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.51x
- Recent ROE (-25.09%) is below the historical average (-22.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -10.11% | -6.49% | 0.34x | 4.53x | $-2.60 Million |
| 2020 | 6.81% | 11.41% | 0.50x | 1.20x | $-1.67 Million |
| 2021 | -6.85% | -26.57% | 0.22x | 1.16x | $-24.12 Million |
| 2022 | -47.52% | -114.60% | 0.27x | 1.52x | $-57.46 Million |
| 2023 | -40.85% | -100.26% | 0.29x | 1.43x | $-45.78 Million |
| 2024 | -32.46% | -70.86% | 0.32x | 1.44x | $-34.98 Million |
| 2025 | -25.09% | -42.59% | 0.39x | 1.51x | $-24.14 Million |
Industry Comparison
This section compares Alpha Teknova Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $379,169,986
- Average return on equity (ROE) among peers: -14.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alpha Teknova Inc (TKNO) | $64.92 Million | -10.11% | 0.52x | $205.34 Million |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $172.65 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $273.24 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.42 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.19 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $37.89 Million | 15.55% | 0.65x | $189.34 Million |
| ANI Pharmaceuticals Inc (ANIP) | $197.26 Million | 7.85% | 1.18x | $1.80 Billion |
About Alpha Teknova Inc
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sam… Read more